# AnalizÄƒ StrategicÄƒ: Eldie â€” Fit pe Strategia V7

**Data analizÄƒ:** 13.02.2026
**Analist:** Edi (Antigravity)
**Status:** ğŸŸ¡ Screening iniÈ›ial â€” pre-Due Diligence
**Categorie V7:** Venture (Early Stage)

---

## 1. Ce face Eldie?

**Ecosistem AI pentru prevenirea È™i detectarea declinului cognitiv la seniori.**

| Element | Detalii |
|---------|---------|
| **Produse** | Jocuri de memorie (grup), Virtual Friend (AI companion), Brain Score (rapoarte cognitive), Family App (insights) |
| **Model B2B** | SaaS pentru cÄƒmine de seniori â€” Ã®nlocuieÈ™te animatorii, reduce costuri cu staff-ul |
| **Target secundar** | Pharma (Alliance Healthcare), Insurance (NN, Allianz Èširiac), Corporations |
| **Ask** | 300-800K EUR pre-seed, la ~5M EUR cap (CLA cu discount TBD) |
| **EchipÄƒ** | 2 cofondatori (CEO + CTO Flavian Dumitrache), 4 FTE total |

---

## 2. TracÈ›iune & Status (ianuarie 2026)

| Metric | Valoare | NotÄƒ |
|--------|---------|------|
| **Revenue actual** | ~0 EUR | Contracte semnate dar Ã®n perioadÄƒ de probÄƒ |
| **Users** | 800+ | Pe aplicaÈ›ie (din piloturi) |
| **CÄƒmine semnate** | 2 | BucureÈ™ti, contracte semnate, 20K EUR/an/cÄƒmin |
| **Usage** | >1h/zi DAU | Mediu pe toÈ›i userii activi |
| **NN** | 50K grant (confirmat) + ofertÄƒ 150-250K/an | CSR + distribuÈ›ie conturi aparÈ›inÄƒtori |
| **Allianz Èširiac** | Ãn discuÈ›ii | Director div. medicale, achiziÈ›ie conturi |
| **Quest for Health** | AcceptaÈ›i | 30K proprii + 120K funded, 3 luni Ã®n FranÈ›a |
| **Growceanu** | 300K committed | Backup din fondul ADR dacÄƒ nu de pe platformÄƒ |
| **GapMinder** | Refuzat (too early) | Investesc min 2M pe fondul nou |
| **Piloturi FranÈ›a** | 2+ cÄƒmine Strasbourg | Planificate |
| **Farmacii** | 10 farmacii paid pilot | 800 EUR/farmacie (8K EUR total) |

---

## 3. Financial Model â€” Numere Cheie

| Metric | An 1 | An 2 | An 6 |
|--------|------|------|------|
| **ClienÈ›i** | ~97 | ~842 | ~2,820 |
| **ARR** | ~2.2M EUR | ~23.5M EUR | ~92M EUR |
| **ARPA/lunÄƒ** | 2,000 EUR | ~2,500 EUR | ~3,150 EUR |
| **FTE** | 6 | 34 | 51 |
| **Marje brute** | ~89% | ~89% | ~89% |
| **Churn lunar** | 2.5% | 2.5% | 2.5% |
| **Financing** | 800K (pre-seed) | 10M (Seria A) | â€” |

âš ï¸ **NotÄƒ:** Modelul financiar e optimist â€” EBITDA pozitiv aproape din luna 1. NecesitÄƒ validare.

---

## 4. Evaluare pe Cei 4 Piloni V7

### ğŸ§‘â€ğŸ’¼ PILON 1: FONDATORI

| # | Parametru | Rating | ObservaÈ›ii |
|---|-----------|:------:|------------|
| F1 | CompetenÈ›e & Skill-uri | âš ï¸ | De evaluat mai Ã®n detaliu. Au lansat MVP funcÈ›ional, dar nu avem date pe experienÈ›Äƒ relevantÄƒ Ã®n healthcare/SaaS |
| F2 | ExperienÈ›Äƒ & Track record | âš ï¸ | Necunoscut suficient din materialele disponibile |
| F3 | Integritate | âš ï¸ | Nu avem suficiente date â€” necesitÄƒ interacÈ›iuni mai profunde |
| F4 | Autenticitate & Asumare | ğŸŸ¢ | Ask-ul a variat (100Kâ†’300Kâ†’800K) â€” poate fi semn de adaptabilitate sau de lipsÄƒ de claritate |
| F5 | Capacitate de a Ã®nvÄƒÈ›a | ğŸŸ¢ | Au aplicat la multiple programe (Quest, J&J), au iterat pe produs |
| F6 | Realism optimist | âš ï¸ | ProiecÈ›iile financiare sunt agresive (97 clienÈ›i an 1, de la 2 acum). Optimism mare, realism de validat |
| F7 | Cultura / EchipÄƒ | âš ï¸ | EchipÄƒ micÄƒ (4 FTE), construcÈ›ie incipientÄƒ |
| F8 | RezilienÈ›Äƒ | âš ï¸ | Insuficiente date |
| F9 | Viziune pe termen lung | ğŸŸ¢ | Viziune clarÄƒ: de la cÄƒmine â†’ pharma â†’ insurance â†’ corporaÈ›ii â†’ B2C |
| F10 | Atragere talent | âš ï¸ | Prea devreme pentru a evalua |
| F11 | Skin in the game | âš ï¸ | Nu avem date |
| F12 | Cofondatori complementari | ğŸŸ¢ | CEO + CTO â€” pare complementar (business + tech) |

**Concluzie Pilon 1:** âš ï¸ **Date insuficiente** â€” Fondatorii sunt cel mai important pilon, dar avem prea puÈ›ine informaÈ›ii. NecesitÄƒ Ã®ntÃ¢lniri directe aprofundate.

---

### ğŸ¢ PILON 2: COMPANIE / MODEL DE BUSINESS

| # | Parametru | Rating | ObservaÈ›ii |
|---|-----------|:------:|------------|
| C1 | Value Proposition | ğŸŸ¢ | ProblemÄƒ realÄƒ: costul animatorilor = 70% din buget cÄƒmin; presiune regulatorie pentru "meaningful activities" |
| C2 | DiferenÈ›iator / Moat | âš ï¸ | AI personalizat + brain score = diferenÈ›iator, dar competiÈ›ia existÄƒ (competitor Accenture, unul Ã®n building stage, un Series A pe B2C). Moat slab deocamdatÄƒ |
| C3 | Go-to-Market | ğŸŸ¢ | B2B direct (cÄƒmine) + parteneriate strategice (NN, Alliance Healthcare, TZMO). GTM prin distributori pare inteligent |
| C4 | Monetizare & RecurenÈ›Äƒ | ğŸŸ¢ | SaaS recurent, 30-60 EUR/senior/lunÄƒ, 2-4K EUR/cÄƒmin/lunÄƒ. Model clar |
| C5 | Unit Economics | âš ï¸ | 89% marje teoretic (SaaS), dar nevalidate pe revenue real. CCC, CAC, LTV â€” toate estimate |
| C6 | Scalabilitate | ğŸŸ¢ | SaaS pur â†’ scalabilitate bunÄƒ pe software. OperaÈ›ional: onboarding cÄƒmine necesitÄƒ effort |
| C7 | Margin of Safety | âš ï¸ | Pre-revenue = MoS intrinsec nu existÄƒ. **La VC, MoS se creeazÄƒ prin Deal Structuring** (LP 1x, anti-dilution). De negociat la CLA |
| C8 | Dispersie clienÈ›i | âš ï¸ | 2 clienÈ›i (cÄƒmine) + 10 farmacii pilot. Concentrare maximÄƒ |
| C9 | OpÈ›iuni pivotare | ğŸŸ¢ | Multiple: B2B cÄƒmine â†’ pharma â†’ insurance â†’ corporation â†’ B2C. EÈ™ecul pe un canal nu blocheazÄƒ celelalte |
| C10 | PotenÈ›ial creÈ™tere TAM | ğŸŸ¢ | Poate creÈ™te piaÈ›a: de la cÄƒmine â†’ asistenÈ›Äƒ la domiciliu â†’ prevenÈ›ie pentru seniori activi |
| C11 | Entry valuation | ğŸŸ¢ | 5M EUR cap; la 0 revenue e standard pre-seed. DacÄƒ ajung la 30 cÄƒmine = 1M ARR, evaluarea ar fi foarte micÄƒ relativ |
| C12 | VitezÄƒ de creÈ™tere | âš ï¸ | Proiectat: 13â†’97 clienÈ›i Ã®n an 1. Optimist. Trebuie validat |
| C13 | Nevoia de capital | âš ï¸ | Pre-seed 300-800K acum, Seria A ~10M peste 12-18 luni. DependenÈ›i de capital extern |
| C14 | Maturitate produs | âš ï¸ | MVP lansat È™i testat, dar pre-PMF. 800 users dar ~0 revenue |
| C15 | Atragere finanÈ›are | ğŸŸ¢ | J&J grant, Quest for Health, Growceanu 300K, discuÈ›ii cu GapMinder. AratÄƒ potenÈ›ial de fundraising |
| C16 | Client feedback | ğŸŸ¢ | >1h/zi usage = engagement puternic. Posibil efect pe reducere churn cÄƒmine |

**Concluzie Pilon 2:** ğŸŸ¡ **Mix** â€” Value proposition puternicÄƒ, model SaaS recurent cu marje bune (teoretic), dar pre-revenue, fÄƒrÄƒ safety net, proiecÈ›ii nevalidate.

---

### ğŸŒ PILON 3: INDUSTRIA

| # | Parametru | Rating | ObservaÈ›ii |
|---|-----------|:------:|------------|
| I1 | TAM | ğŸŸ¢ğŸŸ¢ | 60K cÄƒmine Ã®n Europa Ã— avg 3K EUR/lunÄƒ = ~2.16B EUR/an + B2C (830M seniori global â†’ 1.7B Ã®n 2054). PiaÈ›Äƒ imensÄƒ |
| I2 | CreÈ™tere industrie | ğŸŸ¢ğŸŸ¢ | CAGR 9% (2025-2032) pentru cÄƒmine. ÃmbÄƒtrÃ¢nirea populaÈ›iei = mega-trend global |
| I3 | CompetiÈ›ie & Maturitate | ğŸŸ¢ | PiaÈ›Äƒ emergentÄƒ, fragmentatÄƒ, fÄƒrÄƒ lider dominant. Accenture are o soluÈ›ie hardware dar puÈ›in implementatÄƒ. Timing bun |
| I4 | Trenduri macro | ğŸŸ¢ğŸŸ¢ | Aging population + AI advancement + presiune regulatorie + deficit de personal Ã®n sÄƒnÄƒtate |
| I5 | Buyers strategici | ğŸŸ¢ | Pharma (Alliance Healthcare), insurance (NN, Allianz), corporaÈ›ii â€” potenÈ›iali acquireri È™i/sau strategic partners |
| I6 | DinamicÄƒ localÄƒ RO | âš ï¸ | PiaÈ›a RO e micÄƒ (~puÈ›ine cÄƒmine); valoarea realÄƒ e Ã®n Europa de Vest (FranÈ›a, Germania, UK) |
| I7 | Risc reglementare | âš ï¸ | Healthcare + AI = senzitivitate regulatorie (GDPR, AI Act, date medicale). PotenÈ›ial risc |
| I8 | RezistenÈ›Äƒ cicluri | ğŸŸ¢ | Seniori = cerere non-ciclicÄƒ. CÄƒminele funcÈ›ioneazÄƒ indiferent de economie |
| I9 | Efecte de reÈ›ea | âš ï¸ | Moderate â€” datele agregate (brain score) pot crea avantaj competitiv Ã®n timp, dar nu È™i un moat clasic |

**Concluzie Pilon 3:** ğŸŸ¢ **Foarte favorabil** â€” PiaÈ›Äƒ mare, creÈ™tere acceleratÄƒ, mega-trend demografic, piaÈ›Äƒ emergentÄƒ fÄƒrÄƒ lider. Cel mai puternic pilon.

---

### ğŸ”§ PILON 4: DEAL STRUCTURING

| # | Aspect | ObservaÈ›ii |
|---|--------|------------|
| D1 | **Instrument** | CLA (Convertible Loan Agreement) cu discount TBD la runda urmÄƒtoare. Standard pre-seed |
| D2 | **Cap** | 5M EUR â€” rezonabil pentru pre-seed cu tracÈ›iune iniÈ›ialÄƒ |
| D3 | **Co-investitori** | Growceanu 300K, 2 angels (25K total), NN grant. Sindicalizat |
| D4 | **Ticket V7** | Probabil 50-100K (max 1-1.5% NAV la venture) |
| D5 | **ProtecÈ›ii** | TBD â€” la CLA, protecÈ›iile sunt limitate; depinde de termeni |

---

## 5. Mapare pe Modelul de Asimetrie

### P(win/lose) â€” Probabilitatea de succes

| Factor | ContribuÈ›ie la P | NotÄƒ |
|--------|:---:|------|
| Fondatori | âš ï¸ Neclar | Date insuficiente â€” cel mai mare risc |
| Value Proposition | ğŸŸ¢ Pozitiv | ProblemÄƒ realÄƒ, usage bun |
| TracÈ›iune | âš ï¸ IncipientÄƒ | 800 users, ~0 revenue |
| DiferenÈ›iator | âš ï¸ Slab | Bariere de intrare moderate, competiÈ›ie existentÄƒ |
| Margin of Safety (via Deal) | âš ï¸ De negociat | La VC, MoS se creeazÄƒ prin LP 1x, anti-dilution â€” de inclus Ã®n CLA |
| OpÈ›iuni de pivot | ğŸŸ¢ Pozitiv | Multiple revenue streams posibile |
| Industrie (competiÈ›ie) | ğŸŸ¢ Pozitiv | PiaÈ›Äƒ emergentÄƒ, timing bun |
| **Estimare P(win)** | **20-35%** | Tipic pentru pre-seed SaaS. Risc ridicat |

### Expected Return / Pay-off

| Factor | ContribuÈ›ie la R | NotÄƒ |
|--------|:---:|------|
| TAM | ğŸŸ¢ğŸŸ¢ Foarte mare | 2B+ EUR piaÈ›Äƒ anul, Ã®n creÈ™tere acceleratÄƒ |
| Evaluare intrare | ğŸŸ¢ FavorabilÄƒ | 5M cap la pre-seed = upside masiv dacÄƒ funcÈ›ioneazÄƒ |
| Scalabilitate | ğŸŸ¢ BunÄƒ | SaaS cu 89% marje brute |
| Monetizare | ğŸŸ¢ RecurentÄƒ | 2-4K EUR/lunÄƒ/cÄƒmin, model clar |
| Trenduri macro | ğŸŸ¢ğŸŸ¢ Puternice | Mega-trend global imuabil |
| Buyers strategici | ğŸŸ¢ Exist | Pharma, insurance, healthcare tech |
| **Estimare R potenÈ›ial** | **10-30x MOIC** | DacÄƒ reuÈ™esc scaling european (low probability) |

### Asimetrie: P Ã— R

```
P(win/lose): ~25% (0.20-0.35)
Expected Return: ~10-30x MOIC (dacÄƒ funcÈ›ioneazÄƒ)
Expected Value: 0.25 Ã— 15x = ~3.75x  â†’ POZITIV

Alocare recomandatÄƒ: Max 1-1.5% NAV (venture bucket)
Ticket: 50-100K EUR (la NAV curent ~16.4M = max 245K)
```

> **Concluzie asimetrie:** Asimetrie **pozitivÄƒ** â€” P este scÄƒzut (tipic pre-seed), dar pay-off-ul potenÈ›ial este disproporÈ›ionat. PiaÈ›a e Ã®n creÈ™tere structuralÄƒ imuabilÄƒ (demografia), iar evaluarea este micÄƒ.

---

## 6. Fit pe Strategia V7 â€” Verdict

### âœ… CE SE POTRIVEÈ˜TE

| Criteriu V7 | Eldie | âœ…/âŒ |
|-------------|-------|:---:|
| Sector de interes (aging/longevity) | AI pentru seniori = exact Ã®n categoria "specific trend driven industries" | âœ… |
| Evaluare pre-seed rezonabilÄƒ | 5M cap, standard | âœ… |
| Ticket mic (venture bucket) | 50-100K = sub 1% NAV | âœ… |
| SaaS recurent cu marje mari | 89% GM, model subscription | âœ… |
| TAM mare | 2B+ EUR, growing | âœ… |
| OpÈ›iuni de exit | Pharma, insurance, tech acquirers | âœ… |
| PotenÈ›ial internaÈ›ional | FranÈ›a (Quest for Health), 60K cÄƒmine Ã®n Europa | âœ… |
| Co-investitori validanÈ›i | Growceanu, J&J grant, NN | âœ… |

### âš ï¸ RISCURI / CE NU SE POTRIVEÈ˜TE

| Risc | Severitate | Mitigare posibilÄƒ |
|------|:----------:|-------------------|
| **Pre-revenue** â€” validare piaÈ›Äƒ incompletÄƒ | ğŸ”´ Mare | CLA cu discount = intri mai cheap; poÈ›i aÈ™tepta mai multe date |
| **Fondatori â€” date insuficiente** | ğŸ”´ Mare | Meeting-uri directe obligatorii Ã®nainte de investiÈ›ie |
| **ProiecÈ›ii financiare excesiv de optimiste** | ğŸŸ¡ Mediu | Stress test; 97 clienÈ›i an1 de la 2 acum e agresiv |
| **Moat slab** | ğŸŸ¡ Mediu | Datele (brain score) pot crea moat Ã®n timp, dar nu existÄƒ Ã®ncÄƒ |
| **DependenÈ›Äƒ de capital extern** | ğŸŸ¡ Mediu | Growceanu + Quest valideazÄƒ fundraising ability |
| **Churn 2.5%/lunÄƒ = 30%/an** | ğŸŸ¡ Mediu | Ridicat pentru B2B SaaS. Target <1.5% |
| **PiaÈ›a RO micÄƒ** | ğŸŸ¡ Mediu | Trebuie sÄƒ scaleze Ã®n Europa de Vest rapid |
| **AI/Healthcare regulatory risk** | ğŸŸ¡ Mediu | GDPR, AI Act, date medicale â€” complexitate adÄƒugatÄƒ |
| **Pre-revenue** | ğŸŸ¡ Mediu | MoS intrinsec nu se aplicÄƒ la VC; se creeazÄƒ prin deal structuring (LP 1x) |

---

## 7. Recomandare

### ğŸŸ¢ **POTRIVI**T PE STRATEGIE â€” cu condiÈ›ii

Eldie se Ã®ncadreazÄƒ Ã®n **bucket-ul Venture (10-15% din NAV)** cu un ticket mic (1-1.5% NAV max). Se potriveÈ™te pe:

1. âœ… **Industrie** â€” Aging/longevity, exact Ã®n lista de sectoare de interes V7
2. âœ… **Asimetrie** â€” P scÄƒzut dar R potenÈ›ial mare, ecuaÈ›ia e favorabilÄƒ
3. âœ… **Evaluare** â€” 5M pre-seed, standard, upside mare dacÄƒ funcÈ›ioneazÄƒ
4. âœ… **Model** â€” SaaS recurent, B2B, marje mari

### âš ï¸ CondiÈ›ii Ã®nainte de decizia de investiÈ›ie

| # | AcÈ›iune | Responsabil |
|---|---------|-------------|
| 1 | **Deep dive fondatori** â€” minimum 2 Ã®ntÃ¢lniri directe, evaluare pe F1-F12 | Edi + Iulian |
| 2 | **Stress test financiar** â€” scenarii bear/base/bull pe customer acquisition | Robert |
| 3 | **Verificare tracÈ›iune realÄƒ** â€” validare contracte cÄƒmine, status NN deal | Edi |
| 4 | **Clarificare termeni CLA** â€” discount, cap, pro-rata rights, information rights | Elena |
| 5 | **Due diligence produs** â€” demo live, analiza churn, usage metrics detaliate | Edi |
| 6 | **Competitive landscape** â€” cine e competitorul Seria A pe B2C? Ce face Accenture concret? | Edi/Robert |

---

*AnalizÄƒ realizatÄƒ pe baza: Pitch Deck, NotiÈ›e Edi (oct+ian 2025), Financial Model pre-seed, framework V7 asymmetry_parameters.md*
